Literature DB >> 12027415

Radiotherapy-induced mandibular bone complications.

Barbara A Jereczek-Fossa1, Roberto Orecchia.   

Abstract

The mandible is among the bones most frequently affected by irradiation. The most severe post-radiation injury of the mandible is osteoradionecrosis (ORN). Conflicting data have been reported on the incidence of this complication, its aetiology and management. The incidence of mandibular ORN in head and neck cancer patients managed with radical or postoperative irradiation, has varied widely in the literature from 0.4% to 56%. The interpretation of data derived from particular series are difficult due to the different scoring methods and classification systems used for the evaluation of post-radiation bone damage. Although ORN occurs typically in the first three years after radiotherapy, patients probably remain at indefinite risk. The diagnosis of ORN is principally based on the clinical picture of chronically exposed bone. Radiological symptoms include decreased bone density with fractures, cortical destruction and loss of spongiosa trabeculation. Numerous factors that may be associated with the risk of ORN include treatment-related variables (for example, total radiotherapy dose, biologically effective dose, photon energy, brachytherapy dose rate, combination of external beam irradiation and interstitial brachytherapy, field size, fraction size, volume of the mandible irradiated with a high dose), patient-related variables (like deep parodontitis, pre-irradiation bone surgery, bad oral hygiene, alcohol and tobacco abuse, bone inflammation, dental extraction after radiotherapy) and tumour-related factors (tumour size or stage, proximity of the tumour to bone, anatomic tumour site). Primary management of post-radiation bone lesions include conservative modalities such as saline irrigations, antibiotics during infectious episodes, topically applied antiseptics, gentle sequestrectomy and removal of visibly loosened bone elements as well as treatment with hyperbaric oxygen (HBO). Surgery is reserved for persistent ORN and includes radical resection of the lesion(sequestrectomy, hemimandibulectomy etc.) with reconstruction. In recent years the introduction of preventive oral hygiene measures and meticulous dental evaluations before and after irradiation, improvement in radiotherapy techniques and the development of reliable diagnostic and therapeutic procedures have resulted in a decreased incidence of ORN. Nevertheless, given the severe impact of ORN on patient quality of life, research should be continued to further ameliorate this problem. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12027415     DOI: 10.1053/ctrv.2002.0254

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  52 in total

Review 1.  Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors.

Authors:  Bruno Ramos Chrcanovic; Peter Reher; Alexandre Andrade Sousa; Malcolm Harris
Journal:  Oral Maxillofac Surg       Date:  2010-03

Review 2.  Osteoradionecrosis of the Jaws: Clinico-Therapeutic Management: A Literature Review and Update.

Authors:  Koteswara Rao Nadella; Rama Mohan Kodali; Leela Krishna Guttikonda; Ashok Jonnalagadda
Journal:  J Maxillofac Oral Surg       Date:  2015-03-10

3.  Surgical Management of Skull Base Osteoradionecrosis in the Cancer Population - Treatment Outcomes and Predictors of Recurrence: A Case Series.

Authors:  Ahmed Habib; Matthew M Hanasono; Franco DeMonte; Ali Haider; Jonathan D Breshears; Marc-Elie Nader; Paul W Gidley; Shirley Y Su; Ehab Y Hanna; Shaan M Raza
Journal:  Oper Neurosurg (Hagerstown)       Date:  2020-09-15       Impact factor: 2.703

4.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

5.  Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.

Authors:  Sebastian Hoefert; Inge Schmitz; Andrea Tannapfel; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2009-06-18       Impact factor: 3.573

6.  Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases.

Authors:  Sebastian Hoefert; Inge Schmitz; Frank Weichert; Marcel Gaspar; Harald Eufinger
Journal:  Clin Oral Investig       Date:  2014-06-24       Impact factor: 3.573

7.  Mesenchymal stem cells systemically injected into femoral marrow of dogs home to mandibular defects to enhance new bone formation.

Authors:  Xian Liu; Xuejuan Liao; En Luo; Wenchuan Chen; Chongyun Bao; Hockin H K Xu
Journal:  Tissue Eng Part A       Date:  2014-01-20       Impact factor: 3.845

8.  Periodontal care in patients undergoing radiotherapy for head and neck cancer.

Authors:  Audrey Cristina Bueno; Raquel Conceição Ferreira; Flávia Isabela Barbosa; Bruno Correia Jham; Cláudia Silami Magalhães; Allyson Nogueira Moreira
Journal:  Support Care Cancer       Date:  2012-10-02       Impact factor: 3.603

9.  Oral health status of 207 head and neck cancer patients before, during and after radiotherapy.

Authors:  Bruno C Jham; Patricia M Reis; Erika L Miranda; Renata C Lopes; Andre L Carvalho; Mark A Scheper; Addah R Freire
Journal:  Clin Oral Investig       Date:  2007-09-18       Impact factor: 3.573

10.  Osteo-radio-necrosis (ORN) and bisphosphonate-related osteonecrosis of the jaws (BRONJ): the histopathological differences under the clinical similarities.

Authors:  Konstantinos T Mitsimponas; Patrick Moebius; Kerstin Amann; Philipp Stockmann; Karl-Andreas Schlegel; Friedrich-Wilhelm Neukam; Falk Wehrhan
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.